In Silico Study of Torch Ginger Flower (Etlingera elatior (Jack) R.M.Sm. flos) Bioactive Compounds Targeting TGF-β Receptor Type I (TGF-βR1) as Potential Tumor Suppressor Agents
Abstract
Cancer remains one of the leading causes of death worldwide, with an estimated 16.3 million cancer-related deaths projected by 2040. Current cancer therapies still face various challenges such as resistance, toxicity, and high costs, highlighting the need for more targeted approaches in the discovery of new therapies. Torch ginger flower (Etlingera elatior (Jack) R.M.Sm. flos) has been reported to contain bioactive compounds with potential tumor-suppressive activities through modulation of cancer-related pathways. However, in silico evidence evaluating its active compounds as potential inhibitors of transforming growth factor-beta receptor type I (TGF-βR1), a protein involved in tumor proliferation and metastasis remains limited. This study aimed to predict and evaluate the potential of Etlingera elatior compounds as tumor-suppressing agents targeting TGF-βR1 using computational approaches. Lipinski’s Rule of Five and ADME-Tox predictions were performed to assess drug-likeness and pharmacokinetic properties, while pharmacophore screening and molecular docking were conducted to identify hit compounds and predict their binding affinities. Among the tested compounds, kaempferol and quercetin showed the highest pharmacophore fit scores (47.21% and 47.07%, respectively) and the best binding affinities to TGF-βR1 (-7.98 kcal/mol; Ki 1.42 μM for kaempferol and -7.87 kcal/mol; Ki 1.72 μM for quercetin), and although their binding poses were not the most similar to the reference inhibitor LY3200882 (-8.39 kcal/ mol; Ki 0.71 μM), the consistent alignment of favorable pharmacophore fit and binding energy still reinforces their potential. These findings indicate that kaempferol and quercetin have promising potential as candidate natural tumor-suppressive agents targeting TGF-βR1.
Keywords: Cancer, TGF-βR1, Torch Ginger Flower, Molecular Docking.
Full Text:
PDFReferences
Afladhanti, P.M., Hamzah, H.A., Romadhan, M.D., Putri, S.N., Angelica, E.C., and Theodorus, T., 2023, Etlingera elatior Compounds as Anticancer Agents of Breast Cancer Through Inhibition of Progesterone Receptor: An In Silico Study, Indonesian Journal of Cancer Chemoprevention, 14(2), 94-104.
Baroroh, U., Muscifa, Z.S., Destiarani, W., Rohmatulloh, F.G., and Yusuf, M., 2023, Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer, Indonesian Journal of Computational Biology, 2(1), 22–30.
Cancer Research UK (2023) Worldwide cancer mortality statistics. Available at: https://www. cancerresearchuk.org/health-professional/ cancer-statistics/worldwide-cancer/mortality. (Accessed: 24 May 2025).
Ding Y., and Xue X., 2024, Medicinal Chemistry Strategies for the Modification of Bioactive Natural Products, Molecules, 29(3), 689.
Fadlan, A., and Nusantoro, Y.R., 2021, The effect of energy minimization on the molecular docking of acetone-based oxindole derivatives, Jurnal Kimia dan Pendidikan Kimia, 6(1), 69-77.
Farida, S., and Maruzy, A., 2016, Kecombrang (Etlingera elatior): Sebuah Tinjauan Penggunaan Secara Tradisional, Fitokimia dan Aktivitas Farmakologinya, Indonesian Journal of Plant Medicine,, 9(1), 19–28.
Fariha, R.T., Yuhandiana, S.S., Zubaidah, Pratomo, M.F., and Pertiwi, A.G., 2024, Studi In Silico Potensi Antikanker Pada Senyawa Metabolit Sekunder Buah Makassar, MEDIC NUTRICIA Jurnal Ilmu Kesehatan, 4(3), 25–31.
Guttman, Y., and Kerem, Z., 2022, Computer-Aided (In Silico) Modeling of Cytochrome P450- Mediated Food–Drug Interactions (FDI), International Journal of Molecular Sciences, 23(15), 8498.
Harvey, R.A., and Champe, P.C., 2013, Farmakologi Ulasan Bergambar Edisi 4. Jakarta: EGC.
Krajarng, A., Chulasiri, M., and Watanapokasin, R., 2017, Etlingera elatior Extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akr signaling pathways, BMC Complementary and Alternative Medicine, 17(415), 1–9.
Leonardo-Sousa, C., Barriga, R., Florindo, H.F., Acúrcio, R.C., and Guedes, R.C., 2025, Structural insights and clinical advances in small-molecule inhibitors targeting TGF-β receptor I, Molecular Therapy Oncology, 33(1), 200945.
Lestari, N.A., Isrul, M., Ramadhan, D.S.F., and Fatahu, 2024, Skrining Virtual Berbasis Farmakofor Dari Database Bahan Alam Sebagai Inhibitor Alosterik Mutan T790M/C797 EGFR Untuk Penemuan Obat Kanker Paru, Jurnal Pharmacia Mandala Waluya, 3(3), 168–186.
Lipinski, C.A., 2004, Lead- and drug-like compounds: the rule-of-five revolution, Drug Discovery Today: Technologies, 1(4), 227–241.
Luhung, A., Shefelin, K., Adiputri, N.I., Deliyana, A.N., Colin, M.N., Claudina, N.S.E., and Nuwarda, R.F., 2024, In Silico Study of Flavonoid from Caesalpinia sappan L. against HMG-CoA Reductase as Antihypercholesterolemia, Indonesian Journal of Pharmaceutical Science and Technology, 6(3), 48–57.
Sacan, A., Ekins, S., and Kortagere, S., 2012, Applications and Limitations of In Silico Models in Drug Discovery, in: Larson, R. (eds) Bioinformatics and Drug Discovery. Methods in Molecular Biology, 910. Humana Press, Totowa, NJ.
Shah, U., Patel, N., Patel, M., Rohit, S., Solanki, N., Patel, A., Patel, S., Patel, V., Patel, R., and Jawarkar, R.D., 2024, Computational Exploration of Naturally Occurring Flavonoids as TGF‐β Inhibitors in Breast Cancer: Insights from Docking and Molecular Dynamics Simulations and In‐vitro Cytotoxicity Study, Chemistry & Biodiversity, 21(6).
Siswanto, I., Pranowo, H.D. and Mudasir, M., 2019, Docking of New Designed Compounds Derived from 1,6-Dihydro-1,3,5-triazine-2,4-diamine Toward Quadruple Mutant Plasmodium Dihydrofolate Reductase, Indonesian Journal of Chemistry, 19(3), 777.
Stanzione, F., Giangreco, I., and Cole, J.C., 2021, Use of molecular docking computational tools in drug discovery, Progress in medicinal chemistry, 60, 273–343.
Suryono, S., Amien, M.I., Tohari, A.I., Saputra, A.D., Hidayat, M.R., and Ramadhan, H.F., 2025, In silico studies on quercetin, myricetin, and kaempferol in inhibiting TGF-β1 and galectin-3 for cardiac fibrosis management, Narra J, 5(1), 1310.
Wang, J., Xiang, H., Lu, Y., and Wu, T., 2021, Role and clinical significance of TGF β1 and TGF βR1 in malignant tumors (Review), International Journal of Molecular Medicine, 47, 55.
World Health Organization, 2025, Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer (Accessed: 24 May 2025).
Wulandari, R.P., Gabriel, K., Nurdin, H.A., Pakhrul, D.H.F., Harits, S.S., Prameswari, N., et al., 2023, In Silico Study of Secondary Metabolite Compounds in Parsley (Petroselinum crispum) as a Drug Terapy for Blood Cancer (Myeloproliferative Neoplasm (MPN)) targeting JAK-2, Indonesian Journal of Chemical Science, 12(2), 216–228.
Zhang, Z., Qiao, Y., Yang, L., Chen, Z., Li, T., Gu, M., et al., 2021, Kaempferol 3‐O‐gentiobioside, an ALK5 inhibitor, affects the proliferation, migration, and invasion of tumor cells via blockade of the TGF‐β/ALK5/Smad signaling pathway, Phytotherapy Research, 35(11), 6310– 6323.
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev16iss1pp15-28
Copyright (c) 2026 Yohana Faustine Yuarsa, Garneta Izzati Herdy Putri, Valeri Belliana Sanjaya, Akmal Taufiqur Rahman, Shela Salsabila, Nawadhir Fauzan, Muchtaridi Muchtaridi
Indexed by:
Indonesian Society for Cancer Chemoprevention
